Akebia Receives Nasdaq Bid-Price Deficiency Notice, Has 180 Days to Cure
AKBA is trading near its 52-week low of $0.542 (6.0% above the low).
Summary
Akebia received a Nasdaq notice that its stock has closed below $1.00 for 30 consecutive business days. It has until April 19, 2027 to regain compliance, with a reverse stock split among the options it says it will evaluate.
Key Events · Legal and Risk Events · AKBA
-
Nasdaq Bid-Price Deficiency Notice
On October 21, 2026, Nasdaq notified Akebia that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, breaching Listing Rule 5550(a)(2). The notice has no immediate effect on the listing.
-
180-Day Cure Window to April 19, 2027
Akebia has until April 19, 2027 to close at or above $1.00 for at least 10 consecutive business days. Failing that, it could seek a second 180-day period by meeting all other initial listing standards and committing to a reverse stock split if needed.
-
Reverse Split Flagged as an Option
The company said it will monitor the closing bid price and evaluate options to regain compliance, which could include a reverse stock split, with no assurance it succeeds.
-
Delisting Risk If Cure Fails
If Akebia does not qualify for or complete a second compliance period, Nasdaq would issue a delisting notice; the company could appeal to a Hearings Panel, though it says success is not assured.
Analysis · AKBA · Life Sciences
The clock is now running: Akebia's stock has closed under $1.00 for 30 straight business days, triggering a Nasdaq deficiency letter. Nothing changes today — the shares keep trading — but the company has until April 19, 2027, and its own stated fallback is a reverse stock split. That matters because Akebia is already shrinking: Auryxia revenue is eroding under generic competition and the company posted a $9.1 million net loss in Q1 2026, so a sub-$1 price is a symptom of the same pressure, not an isolated technicality. A reverse split would fix the bid price on paper without changing the underlying business, and it would come alongside the CCO departure disclosed on October 14, 2026.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1025 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKBA was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.1M. The 52-week trading range was $0.54 to $3.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.